Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Solid Biosciences' Current Deferred Revenue history spans 3 years, with the latest figure at $6.2 million for Q1 2022.

  • For Q1 2022, Current Deferred Revenue fell 65.07% year-over-year to $6.2 million; the TTM value through Mar 2022 reached $6.2 million, down 65.07%, while the annual FY2021 figure was $8.1 million, 61.0% down from the prior year.
  • Current Deferred Revenue for Q1 2022 was $6.2 million at Solid Biosciences, down from $8.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $20.7 million in Q4 2020 and bottomed at $6.2 million in Q1 2022.
  • The 3-year median for Current Deferred Revenue is $14.4 million (2020), against an average of $12.9 million.
  • The largest annual shift saw Current Deferred Revenue changed 0.0% in 2021 before it crashed 65.07% in 2022.
  • A 3-year view of Current Deferred Revenue shows it stood at $20.7 million in 2020, then plummeted by 61.0% to $8.1 million in 2021, then decreased by 23.64% to $6.2 million in 2022.
  • Per Business Quant, the three most recent readings for SLDB's Current Deferred Revenue are $6.2 million (Q1 2022), $8.1 million (Q4 2021), and $8.9 million (Q3 2021).